AI assistant
Intrasense Regulatory Filings 2021
1447_iss_2021-10-05_f5a0b738-83f6-4d87-a59b-15f6f3fbf6c0.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Press release Montpellier, France, October 5, 2021 – 5:45pm CEST
New product line in oncology: a milestone passed with the signature of a partnership between Intrasense and I-SERIS
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the medical imaging and radiology group I-SERIS, which includes the clinics of Clémentville (Montpellier), Clermont l'Hérault and the scanner center of the Pasteur clinic in Pézenas, announce the signing of an agreement for the development of the new oncology solution Myra.
Myra, an intelligent oncology platform
The future Myra oncology product line, whose development was announced by Intrasense during its capital increase occurred in June 2021, aims to place the patient at the center of the imaging care pathway and enable comprehensive management, from screening to follow-up, through multidisciplinary collaboration.
With the ambition to organize the different radiology workflows, user experience and clinical value will be major assets of the new Intrasense platform. The artificial intelligence incorporated in the solution is also a significant asset to improve diagnostic accuracy and efficiency.
In this context, the collaboration with renowned players and experts in medical imaging and oncology are considerable benefits. Thus, the signature of this partnership agreement is a structuring step in the development of Myra.
I-SERIS, a major player in radiology in Occitania
The I-SERIS group, established on several sites in Occitania, is a major regional player in the field of radiology and particularly oncological imaging. The group is established in Montpellier with the Clémentville clinic, in Clermont l'Hérault as well as in Pézenas with the scanner center of the Pasteur clinic. I-SERIS is a member of the VIDI network, which includes 52 imaging centers and 900 radiologists in France.
The I-SERIS group specializes in diagnostic and interventional radiology, particularly for oncology. The company is structured in units: oncology, oncohaematology, women's and children's imaging, musculoskeletal imaging, thoracic imaging, digestive and urinary imaging and emergency imaging.
A partnership based on know-how and expertise in oncology
The agreement includes the contribution of the I-SERIS group to the definition and validation of the future Myra solution's functionalities, access to anonymized data for the development and validation of the solution by Intrasense, as well as the provision by Intrasense to the I-SERIS group of the first versions of the solution for validation and promotion purposes.
Nicolas Reymond, CEO of Intrasense, stated: "We are very pleased to collaborate with I-SERIS, a major medical player in our ecosystem. The pooling of our expertise will be a great accelerator for our developments. Intrasense puts user experience and medical value at the heart of its new product line strategy and we are proud to be able to rely on the experts of the I-SERIS group. This partnership is a major step in our innovation strategy."
About Intrasense
Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr
About I-SERIS
A major actor in oncology imaging in Occitania, with 3 fully digitized imaging centers with secure broadcasting, I-SERIS brings together radiologists specialized by anatomical area and by imaging activity centers. I-SERIS is affiliated to the VIDI network. More information on : www.radiologie-montpellier.fr
About Vidi
Vidi network is a pioneer in French liberal radiology. Through its independence, Vidi defends a medical project for the benefit of the quality of care for all patients. Thanks to its national network, Vidi facilitates access to excellence of diagnostics and care, as well as specialist radiologists in all areas of expertise, spread across France. The Vidi cooperative network brings together 52 medical imaging centers and nearly 900 radiologists. All are mobilized to perform the most relevant and efficient medical imaging examinations throughout the care pathway, from screening to interventional, from diagnosis to treatment. For more information, www.groupe-vidi.fr.
Contacts
Intrasense Jérémy Peyron Marketing & Communication manager 1231 avenue du Mondial 98, 34000 Montpellier, FRANCE Tel: +334 67 130 130 [email protected]
NewCap Investor Relations and Financial Communication Louis Tilquin Paris, FRANCE Tel: +331 44 71 20 40 [email protected]